NDA 214044 · Rosemont
Qdolo
Tramadol Hydrochloride · Oral
DiscontinuedLast checked: Nov 19, 2026Latest source record: Jun 18, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Sep 1, 2020
Approved uses
1
Original approval plus efficacy supplements
Registered trials
477
87 Phase 3, 25 recruiting
FAERS reports
38,125
34,463 serious, 7,644 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
WARNING: RISK OF MEDICATION ERRORS; ADDICTION, ABUSE, and MISUSE; RISK EVALUATION and MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; ULTRA-RAPID METABOLISM OF TRAMADOL and OTHER RISK FACTORS FOR LIFE-THREATENING RESPIRATORY DEPRESSION IN CHILDREN; NEONATAL OPIOID WITHDRAWAL SYNDROME; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS WARNING: RISK OF MEDICATION ERRORS; ADDICTION, ABUSE, and MISUSE; RISK EVALUATION and MITIGATION STRATEGY (REMS); LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; ULTRA-RAPID METABOLISM OF TRAMADOL and OTHER RISK FACTORS FOR LIFE-THREATENING RESPIRATORY DEPRESSION IN CHILDREN; NEONATAL OPIOID WITHDRAWAL SYNDROME; INTERACTIONS WITH DRUGS AFFECTING CYTOCHROME P450 ISOENZYMES; and RISKS FROM CONCOMITANT USE WITH...
What it is approved for
From the label in effect Jan 25, 2023.
Tramadol hydrochloride oral solution is indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Tramadol hydrochloride oral solution is an opioid agonist indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate ( 1 ). Limitations of Use ( 1 ) Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses ( 5.2 ), reserve tramadol hydrochloride oral solution for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: Have not been tolerated or are not expected to be tolerated ( 1 ). Have not provided adequate analgesia, or are not expected to provide adequate analgesia ( 1 ). Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions ( 5.2 )] , reserve tramadol hydrochloride oral solution for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: Have not been tolerated or are not expected to be tolerated. Have not provided adequate analgesia or are not expected to provide adequate analgesia.
Mechanism: Tramadol hydrochloride oral solution contains tramadol, an opioid agonist and inhibitor of norepinephrine and serotonin re-uptake. Although the mode of action is not completely understood, the analgesic effect of tramadol is believed to be due to both binding to µ-opioid receptors and weak inhibition of re-uptake of norepinephrine and serotonin. Opioid activity is due to both low affinity binding of the parent compound and higher affinity binding of the O -demethylated metabolite M1 to µ-opioid receptors. In animal models, M1 is up to 6 times more potent than tramadol in producing analgesia...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 1, 2020 Original approval · Type 3 - New Dosage Form LabelMedication GuideLetter
1 products under this application
- QDOLO · TRAMADOL HYDROCHLORIDE 5MG/ML · SOLUTION, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Tramadol" as an intervention, any sponsor and status, largest first.
- Comparison of Pain Therapeutic Effects After Benign MastectomyPivotal-lookingCompleted
Nanjing Medical UniversityAcademic, hospital or other
NCT00519246 · 2,000 participants · Start Feb 2007 · Primary completion Dec 2007
Drug: Saline; Opioid and 5 more · For: Pain, Postoperative; Mastectomy
Sites: Nanjing, China
- A Phase 3 Study of Tanezumab for Chronic Low Back PainPivotal-lookingCompleted
PfizerPfizer (PFE)
NCT02528253 · 1,832 participants · Start Aug 18, 2015 · Primary completion Oct 17, 2017
Drug: Placebo to Week 16; tanezumab 5mg SC; Placebo to Week 16, tanezumab 10 mg SC and 3 more · For: Low Back Pain
Sites: Birmingham, Alabama; Mobile, Alabama; Saraland, Alabama · 262 sites in all
- MAST Trial: Multi-modal Analgesic Strategies in TraumaPivotal-lookingCompleted
The University of Texas Health Science Center, HoustonAcademic, hospital or other
NCT03472469 · 1,561 participants · Start Apr 2, 2018 · Primary completion Jul 3, 2019
Drug: Acetaminophen IV/PO; Acetaminophen PO and 9 more · For: Nonspecific Pain Post Traumatic Injury
Sites: Houston, Texas
- Paracetamol-Tramadol and Paracetamol-caffeine Versus Placebo in the Emergency Discharge Treatment of Renal ColicPivotal-lookingStatus unknown
University of MonastirAcademic, hospital or other
NCT06345716 · 1,500 participants (planned) · Start Apr 10, 2024 · Primary completion Mar 15, 2025
Drug: paracétamol tramadol; Paracétamol cafeine and 1 more · For: Renal Colic
Sites: Monastir, Tunisia
- Effect of Early Pain Management at Triage on Opioid ConsumptionPivotal-lookingCompleted
University of MonastirAcademic, hospital or other
NCT03243006 · 1,500 participants · Start Jan 1, 2016 · Primary completion Sep 30, 2016
Drug: Paracetamol; Tramadol/Paracetamol combination and 1 more · For: Acute Pain
- Effect of Tramadol in Prevention of Postpartum DepressionPivotal-lookingCompleted
Xinqiao Hospital of ChongqingAcademic, hospital or other
NCT03309163 · 1,230 participants · Start Oct 9, 2017 · Primary completion Jun 13, 2019
Drug: Tramadol; Hydromorphone and 1 more · For: Caesarean Section
Sites: Chongqing, China
- Tramadol/Diclofenac Fixed-dose Combination Phase III Trial in Acute Pain After Third Molar ExtractionPivotal-lookingCompleted
Grünenthal GmbHIndustry
NCT03714672 · 1,151 participants · Start Aug 26, 2017 · Primary completion Mar 9, 2018
Drug: Tramadol/Diclofenac 50/50; Tramadol/Diclofenac 25/25 and 2 more · For: Acute Pain
Sites: Zapopan, Mexico; Monterrey, Mexico; Aguascalientes, Mexico · 8 sites in all
- Efficacy and Safety in a Randomised Acute Pain Study of MR308: STARDOM2.Pivotal-lookingCompleted
Mundipharma Research GmbH & Co KGIndustry
NCT03062644 · 1,138 participants · Start Apr 5, 2017 · Primary completion Jun 29, 2018
Drug: MR308; MR308 and 2 more · For: Acute Pain
Sites: Minsk, Belarus; Sofia, Bulgaria; London, Canada · 8 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dependence7,835
- overdose3,935
- vomiting3,558
- pain3,205
- nausea3,006
- drug ineffective2,824
- dyspnoea2,557
- off label use2,551
- headache2,496
- fatigue2,488
- drug hypersensitivity2,376
- drug dependence2,205
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 115 |
| 2005 | 129 |
| 2006 | 94 |
| 2007 | 50 |
| 2008 | 124 |
| 2009 | 230 |
| 2010 | 564 |
| 2011 | 492 |
| 2012 | 936 |
| 2013 | 669 |
| 2014 | 631 |
| 2015 | 990 |
| 2016 | 1,030 |
| 2017 | 1,555 |
| 2018 | 1,820 |
| 2019 | 2,299 |
| 2020 | 2,128 |
| 2021 | 2,974 |
| 2022 | 2,924 |
| 2023 | 9,952 |
| 2024 | 3,702 |
| 2025 | 2,810 |
| 2026 | 1,905 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Tramadol versus placebo for chronic pain: a systematic review with meta-analysis and trial sequential analysis.
Barakji JA, Maagaard M, Petersen JJ, et al. · BMJ Evid Based Med 2026 · Systematic Review, Meta-Analysis
- Tramadol (with or without acetaminophen) efficacy and harm: Systematic review and meta-analysis.
Otte JA, Chu G, Heran B, et al. · Can Fam Physician 2025 · Systematic Review, Meta-Analysis
- Efficacy of tramadol for postoperative pain management in dogs: systematic review and meta-analysis.
Donati PA, Tarragona L, Franco JVA, et al. · Vet Anaesth Analg 2021 · Meta-Analysis, Systematic Review
- Tramadol for neuropathic pain.
Hollingshead J, Dühmke RM, Cornblath DR · Cochrane Database Syst Rev 2006 · Meta-Analysis, Systematic Review
- Tramadol for neuropathic pain.
Duhmke RM, Cornblath DD, Hollingshead JR · Cochrane Database Syst Rev 2004 · Meta-Analysis, Systematic Review
- Tramadol and the occurrence of seizures: a systematic review and meta-analysis.
Nakhaee S, Amirabadizadeh A, Brent J, et al. · Crit Rev Toxicol 2019 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: Rosemont
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.